Inovio Pharmaceuticals (INO) Posts Narrower than Expected Q2 Loss of 18c/Share

Inovio Pharmaceuticals, Inc. (AMEX: INO) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $1.8 million.

Dr. J. Joseph Kim, President and CEO, said, "Our second quarter marked a historical step for Inovio with the reporting of positive efficacy data from our HPV immunotherapeutic phase II study. We are extremely pleased with the comprehensive data outcomes of this study, including an impressive level of complete CIN 2/3 clearance, and their implications for VGX-3100 to potentially fulfill a significant unmet need as a non-surgical first-line treatment alternative for these cervical precancers. We are now in a position every biotechnology company hopes to reach, which is to have a product candidate with the merit to advance into a phase III registration study on the path toward commercialization. We are now making that commitment with VGX-3100.

"Apart from the positive outcome for our HPV franchise, this exciting data opens many new doors for the advancement and expansion of our broad cancer and infectious disease immune therapy developments. We are on the right path toward creating important and valuable therapies to help mankind."

For earnings history and earnings-related data on Inovio Pharmaceuticals, Inc. (INO) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• SkyWest (SKYW) Tops Q1 EPS by 28c, Beats on Revenue